Tumor-associated peptides that bind to MHC-molecules

Details Tumor-associated peptides that bind to MHC-molecules Tumor-associated peptides that bind to MHC-molecules

2011-08-30

2011-08-30

Yu, Misook (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C436S023000, C435S069100

Reexamination Certificate

active

08008431

ABSTRACT:
The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibilityg complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.

REFERENCES:
patent: 5831016 (1998-11-01), Wang et al.
patent: 5955314 (1999-09-01), Hillman et al.
patent: 6410240 (2002-06-01), Hodge et al.
patent: 2002/0061543 (2002-05-01), Ross
patent: 2003/0113733 (2003-06-01), Khan et al.
patent: 2005/0063967 (2005-03-01), Young
patent: 102 25 144 (2003-12-01), None
patent: 10225144 (2003-12-01), None
patent: WO2002057420 (2002-07-01), None
patent: WO 2004015390 (2004-02-01), None
patent: WO2004031210 (2004-04-01), None
Sequence search result , 2010.
Harig et al, Blood, vol. 98, p. 2999-3005, 2001.
Sequence search result (Sette) 2010.
Sequence search result (Moore) 2010.
Sequence search result (Hillman) 2010.
Krüge et al Cancer Immunol Immunother vol. 54:826-836, online published Dec. 2004 (R5, IDS filed Jul. 12, 2007).
Dejgaard, K. et al., “Identification, Molecular Cloning, Expression and Chromosome Mapping of a Family of Transformation Upregulated hnRNP-K Proteins Derived by Alternative Splicing,”J. Mol. Biol., 1994, vol. 236, No. 1, pp. 33-48, XP-002963154.
Flad, T. et al., “Direct Identification of Major Histocompatibility Complex Class I-bound Tumor-associated Peptide Antigens of a Renal Carcinoma Cell Line by a Novel Mass Spectrometric Method,”Cancer Research, Dec. 15, 1998, vol. 58, No. 24, pp. 5803-5811, XP-001161018.
Furuya, M. et al., “Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma,”Journal of Pathology, Feb. 18, 2004, vol. 203, No. 1, pp. 551-558.
Hofmann, S. et al., “Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by nanoLC MALDI MS/MS,”MCP In Press, Aug. 19, 2005, XP-002344047.
Krüger, T. et al., “Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy,”Cancer Immunol. Immunother., Sep. 2005, vol. 54, No. 9, pp. 826-836, XP-002344048.
Lemmel, C. “Dissertation: Qualitative und quantitative Analyse krankheitsassoziierter MHC-Klasse-I-Liganden durch massenspektrometrische Verfahren,” <http://w210.ub.uni-tuebingen.de/dbt/volltexte/2004/1287/pdf/Lemmel—Dissertation.pdf>, Jun. 24, 2004, XP002344158.
Melief, C. et al., “Peptide-based cancer vaccines,”Current Opinion in Immunology, 1996, vol. 8, No. 5, pp. 651-657, XP-002344045.
Purcell, A.W. et al., “Immunoproteomics: Mass Spectrometry-Based Methods to Study the Targets of the Immune Response,”Molecular&Cellular Proteomics, Mar. 2004, vol. 3, No. 3, pp. 193-208, XP-002344046.
Schirle, M. et al., “Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach,”Eur. J. Immunol., Aug. 2000, vol. 30, No. 8, pp. 2216-2225, XP-002246625.
A.W. Purcell et al.: Immunoproteomics “Mass Spectrometry-Based Methods to Study the Targets of the Immune Response”, Molecular & Cellular Proteomics 3.3 2004, pp. 193-208 The American Society and Biochemistry and Molecular Biology. Inc. XP-002344046.
Claudia Lemmel et el. “Differential Quantitative Analysis of MHC Ligands by Mass Spectrometry Using Stable Isotope Labeling”. Nature Biotechnology, Nature Publising Group, New York, NY, US, BD.22 NR. 4, Apr. 1, 2004, 450-454, XP002359085, ISSN 1087-0156.
G. Pluschke et al: “Molecular Cloning of a 3, 15 Human Melanoma-Associated Chondroitin Sulfate Proteoglycan” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, US, BD. 93, NR. 18, Sep. 1, 1996, 9710-9715, XP003019023, ISSN: 0027-8424.
Database Geneseq [Online], “Human Brain Expressed Single Exon Probe Encoded Protein Seq Id No: 25597.” Nov. 5, 2001, XP002521875, EBI Accession No. GSP:AAM53492, Database Accession No. AAM53492.
Database Geneseq [Online], “Propionibacterium Acnes Immunogenic Protein # 19260” XP002521879, Feb. 27, 2002. EBI Accession No. GSP:AAU58364, Database Accession No. AAU58364.
T. Flad et al: “Direct Identification of Major Histocompatibility Complex Class I-Bound Tumor-Associated Peptide Antigens of a Renal Carcinoma Cell Line by a Novel Mass Spectrometic Method”, Cancer Research, American Association for Cancer Research, Baltimore, MD, US, BD. 58, NR. 24, Dec. 15, 1998.
Tobias Krueger et al.: “Lessons to Be Learned From Primary Renal Cell Carcinomas: Novel Tumor Antigens and HLA Ligands for Immunotherapy.” Cancer Immunology. Immunotherapy CII. Sep. 2005, BD. 54, NR. 9, 826-836, XP002344048 ISSN: 0340-7004.
Stefan Stevanovic et al.: “Generating Data 1-17 for Databases—The Peptide Repertoire of HLA Molecules”. Novartis Foundation Symposium, Wiley, Chester, GB, BD 254, Jan. 1, 2003, 143-252: XP009105681; ISSN: 1528-2511.
Markus Shirle et al. “Identification of 1-17 Tumor-Associated MHC Class I Ligands by a Novel T Cell-Independent Approach” European Journal O Fimmunology. Weinheim DE. BD/3 NR Aug. 8, 2008, 2216-2225, XXP002246625, ISSN: 0014-2980.
Cornelis J.M. Melief. et al.: “Peptide-Based Cancer Vaccines” Current Opinion in Immunology BD. 8, NR. 5, 1996, 651-657, XP002344045, ISSN: 0952-7915.
Search Report for EP 09000315 Dated Mar. 31, 2009.
Rammensee et al., “SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics”, Nov. 1999, pp. 213-219, Springer-Verlag.

Affiliated with

Also associated with

Rating

Tumor-associated peptides that bind to MHC-molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor-associated peptides that bind to MHC-molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-associated peptides that bind to MHC-molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2759102